Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Cancer cells possess genomic instability, a key characteristic influencing therapeutic responses.
• Targeted cancer therapies, such as monoclonal antibodies and kinase inhibitors, aim to induce direct cell death.
• Genomic instability can paradoxically enhance the effectiveness of immunotherapies by generating tumor neoantigens.

Purpose of the Study:

• To provide an overview of current cancer therapeutics, including targeted agents and immunotherapies.
• To discuss how cancer cell genomic instability impacts therapeutic strategies.
• To advocate for combinatorial approaches integrating targeted and immune-based therapies.

Main Methods:

• Review of existing literature on cancer therapeutics, focusing on targeted agents and immunotherapies.
• Analysis of the role of genomic instability in cancer development and treatment response.
• Conceptual framework for combinatorial cancer treatment strategies.

Main Results:

• Genomic instability complicates direct tumor cell killing by targeted therapies.
• The same instability generates neoantigens, increasing the potential for immune recognition and attack.
• Combinatorial strategies can leverage tumor antigen release and immune checkpoint interference.

Conclusions:

• Integrating targeted therapies that induce antigen release with immunotherapies that overcome immune suppression is a promising strategy.
• Exploiting cancer's genomic instability is crucial for developing effective combination treatments.
• Future cancer therapy should focus on synergistic approaches to enhance anti-tumor immunity and treatment efficacy.